Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)

Clinical trial NCT04529564 · COMPLETED

Trial details

NCT number: NCT04529564
Sponsor: AstraZeneca
Status: COMPLETED
Study type: OBSERVATIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2020-06-12
Primary completion: 2023-06-29
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.